The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

Neta Zuckerman; Ital Nemet; Limor Kliker; Nofar Atari; Yaniv Lustig; Efrat Bucris; Dana Bar Ilan; Miranda Geva; Reut Sorek-Abramovich; Chen Weiner; Nir Rainy; Adina Bar-Chaim; Patricia Benveniste-Levkovitz; Ramzia Abu Hamed; Gili Regev-Yochay; Ofra Hevkin; Orna Mor; Sharon Alroy-Preis; Ella Mendelson; Michal Mandelboim

doi:10.2807/1560-7917.ES.2021.26.45.2100974

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

Neta Zuckerman, Ital Nemet, Limor Kliker, Nofar Atari, Yaniv Lustig, Efrat Bucris, Dana Bar Ilan, Miranda Geva, Reut Sorek-Abramovich, Chen Weiner, Nir Rainy, Adina Bar-Chaim, Patricia Benveniste-Levkovitz, Ramzia Abu Hamed, Gili Regev-Yochay, Ofra Hevkin, Orna Mor, Sharon Alroy-Preis, Ella Mendelson, Michal Mandelboim

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Microneutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

Original language	English
Article number	pii=2100974
Journal	Eurosurveillance
Volume	26
Issue number	45
DOIs	https://doi.org/10.2807/1560-7917.ES.2021.26.45.2100974
State	Published - 1 Nov 2021
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2021 European Centre for Disease Prevention and Control (ECDC). All rights reserved.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2807/1560-7917.ES.2021.26.45.2100974

Cite this

Zuckerman, N., Nemet, I., Kliker, L., Atari, N., Lustig, Y., Bucris, E., Bar Ilan, D., Geva, M., Sorek-Abramovich, R., Weiner, C., Rainy, N., Bar-Chaim, A., Benveniste-Levkovitz, P., Hamed, R. A., Regev-Yochay, G., Hevkin, O., Mor, O., Alroy-Preis, S., Mendelson, E., & Mandelboim, M. (2021). The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021. Eurosurveillance, 26(45), Article pii=2100974. https://doi.org/10.2807/1560-7917.ES.2021.26.45.2100974

@article{e0e5946cc09e4aa38935ea699d7edd7e,

title = "The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021",

abstract = "The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Microneutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.",

author = "Neta Zuckerman and Ital Nemet and Limor Kliker and Nofar Atari and Yaniv Lustig and Efrat Bucris and {Bar Ilan}, Dana and Miranda Geva and Reut Sorek-Abramovich and Chen Weiner and Nir Rainy and Adina Bar-Chaim and Patricia Benveniste-Levkovitz and Hamed, {Ramzia Abu} and Gili Regev-Yochay and Ofra Hevkin and Orna Mor and Sharon Alroy-Preis and Ella Mendelson and Michal Mandelboim",

year = "2021",

month = nov,

day = "1",

doi = "10.2807/1560-7917.ES.2021.26.45.2100974",

language = "אנגלית",

volume = "26",

journal = "Eurosurveillance",

issn = "1025-496X",

publisher = "European Centre for Disease Prevention and Control (ECDC)",

number = "45",

}

Zuckerman, N, Nemet, I, Kliker, L, Atari, N, Lustig, Y, Bucris, E, Bar Ilan, D, Geva, M, Sorek-Abramovich, R, Weiner, C, Rainy, N, Bar-Chaim, A, Benveniste-Levkovitz, P, Hamed, RA, Regev-Yochay, G, Hevkin, O, Mor, O, Alroy-Preis, S, Mendelson, E & Mandelboim, M 2021, 'The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021', Eurosurveillance, vol. 26, no. 45, pii=2100974. https://doi.org/10.2807/1560-7917.ES.2021.26.45.2100974

TY - JOUR

T1 - The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

AU - Zuckerman, Neta

AU - Nemet, Ital

AU - Kliker, Limor

AU - Atari, Nofar

AU - Lustig, Yaniv

AU - Bucris, Efrat

AU - Bar Ilan, Dana

AU - Geva, Miranda

AU - Sorek-Abramovich, Reut

AU - Weiner, Chen

AU - Rainy, Nir

AU - Bar-Chaim, Adina

AU - Benveniste-Levkovitz, Patricia

AU - Hamed, Ramzia Abu

AU - Regev-Yochay, Gili

AU - Hevkin, Ofra

AU - Mor, Orna

AU - Alroy-Preis, Sharon

AU - Mendelson, Ella

AU - Mandelboim, Michal

PY - 2021/11/1

Y1 - 2021/11/1

N2 - The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Microneutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

AB - The SARS-CoV-2 Lambda (Pango lineage designation C.37) variant of interest, initially identified in Peru, has spread to additional countries. First detected in Israel in April 2021 following importations from Argentina and several European countries, the Lambda variant infected 18 individuals belonging to two main transmission chains without further spread. Microneutralisation assays following Comirnaty (BNT162b2 mRNA, BioNTech-Pfizer) vaccination demonstrated a significant 1.6-fold reduction in neutralising titres compared with the wild type virus, suggesting increased susceptibility of vaccinated individuals to infection.

UR - http://www.scopus.com/inward/record.url?scp=85120942100&partnerID=8YFLogxK

U2 - 10.2807/1560-7917.ES.2021.26.45.2100974

DO - 10.2807/1560-7917.ES.2021.26.45.2100974

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 34763751

AN - SCOPUS:85120942100

SN - 1025-496X

VL - 26

JO - Eurosurveillance

JF - Eurosurveillance

IS - 45

M1 - pii=2100974

ER -

The SARS-CoV-2 Lambda variant and its neutralisation efficiency following vaccination with Comirnaty, Israel, April to June 2021

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this